Loading
A phase 3 trial testing BEBT-209 in HR-positive / HER2-negative breast cancer, now recruiting.
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy is a phase 3 interventional study registered as NCT06998108, led by BeBetter Med with Chinese Academy of Medical Sciences, and recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy. Planned enrolment is 330 participants (estimated). The study started in 2022-06-09 and primary completion is expected in 2025-12-31. No results have been posted on ClinicalTrials.gov.